The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Lutathera supports improved survival for patients with neuroendocrine tumors
Novartis’ Lutathera, a drug indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, including foregut, midgut, and hindgut tumors, was recently highlighted at the World Congress on Gastrointestinal Cancer 2021. Dr. Jonathan R. Strosberg, head of the Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in…